Company intelligence / Profile preview

Aureon Laboratories

Yonkers, New York, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

A 2009 peer-reviewed study published in the Journal of Urology demonstrated that Aureon's patented approach of integrating morphometry and biomarker data with clinical information improved accuracy for identifying patients most likely to develop prostate cancer disease progression post-surgery[3].

Therapeutic areas: Oncology
Modalities: Tissue-based diagnosticsMolecular diagnosticsImage analysis
Industry: Pathology

Partnerships

Bio-pharmaceutical partners for drug discovery and clinical developmentcollaboration with academic institutions

Beyond the preview

Go deeper on Aureon Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aureon Laboratories.

Explore the full profile